Influence of ezetimibe monotherapy on ischemiamodified albumin levels in hypercholesterolemic patients

Pharmacological Reports

Volumn 63, Issue 5, 2011, Pages 1248-1251

  Kotani, Kazuhiko ^a,b,c   Caccavello, Russell ^c   Sakane, Naoki ^a   Miyamoto, Michiaki ^b   Gugliucci, Alejandro ^c  

^a NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c TOURO UNIVERSITY CALIFORNIA   (United States)

Author keywords

Atherosclerosis; IMA; Intestinal cholesterol transport inhibitor; Oxidative stress; Reactive oxygen species

Indexed keywords

EZETIMIBE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISCHEMIA MODIFIED ALBUMIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIA; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; OXIDATIVE STRESS; PROSPECTIVE STUDY;

EID: 83155175606     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70646-6     Document Type: Article

References (16)

1. Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO et al.: A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther, 2004, 26, 1758-1773. (Pubitemid 40089489)
2. Bhagavan NV, Lai EM, Rios PA, Yang J, Ortega-Lopez AM, Shinoda H, Honda SA et al.: Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem, 2003, 49, 581-585. (Pubitemid 36379523)
3. Betters JL, Yu L: NPC1L1 and cholesterol transport. FEBS Lett, 2010, 584, 2740-2747.
4. Cohn JS: Postprandial lipemia: emerging evidence for atherogenicity of remnant lipoproteins. Can J Cardiol, 1998, 14, B18-27.
5. Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M, Ishii H, Yoshida M: Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett, 2007, 581, 5664-5670. (Pubitemid 350179776)
6. Duarte MM, Rocha JB, Moresco RN, Duarte T, Da Cruz IB, Loro VL, Schetinger MR: Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem, 2009, 42, 666-671.
7. Fukuda M, Nakamura T, Kataoka K, Nako H, Tokutomi Y, Dong YF, Yasuda O et al.: Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice. J Pharmacol Exp Ther, 2010, 335, 70-75.
8. Jagla A, Schrezenmeir J: Postprandial triglycerides and endothelial function. Exp Clin Endocrinol Diabetes, 2001, 109, S533-547. (Pubitemid 32577696)
9. Lioudaki E, Ganotakis ES, Mikhailidis DP: Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. Curr Vasc Pharmacol, 2011, 9, 62-86.
10. Nakajima K, Nakano T, Tanaka A: The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta, 2006, 367, 36-47.
11. Sbarouni E, Georgiadou P, Voudris V: Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med, 2011, 49, 177-184.
12. Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP, Collinson PO, Brecker SJ: Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis, 2006, 47, 493-502. (Pubitemid 43255184)
13. Turfaner N, Uzun H, Balci H, Ercan MA, Karter YH, Caner M, Sipahioglu F, Genc H:. Ezetimibe therapy and its influence on oxidative stress and fibrinolytic activity. South Med J, 2010, 103, 428-433.
14. Ueda S, Miyake I, Takata K, Shimizu N, Shirotani K, Ishida S, Yonemitsu K et al.: Ezetimibe, an inhibitor of intestinal cholesterol absorption, decreases serum level of malondialdehyde-modified low-density lipoprotein in patients with hypercholesterolemia. Int J Cardiol, 2011, 146, 420-421.
15. Van Belle E, Dallongeville J, Vicaut E, Degrandsart A, Baulac C, Montalescot G: Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study. Am Heart J, 2010, 159, 570-576.
16. Victor VM, Rocha M, Solá E, Bañuls C, Garcia-Malpartida K, Hernández-Mijares A: Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des, 2009, 15, 2988-3002.